CASSINI Trial publishes data on preventing blood clots in cancer patients

Researchers have published the first clinical study investigating the use of the direct oral anticoagulant, rivaroxaban, to prevent blood clots in patients with cancer at high-risk. The study found no significant reduction in venous thromboembolism or death in the overall 180-day trial period; however, the researchers did observe a lower incidence of these events while patients were actively on the study drug, or during the on-treatment period.

Leave a Reply

Your email address will not be published.